Module C: 14-17 Flashcards
(84 cards)
1
Q
Describe the phases of the action potential of the autorhythmic cells of the heart, including the involvement of ion channels:
A
Phase 4: Pacemaker potential arises from “funny current” as sodium enters cell slowly through HCN channels. Membrane slowly depolarizes from -60 to -40mV
Phase 0: Membrane reaches threshold potenential and L-type Ca2+ channels open. Rapid depolarization from calcium influx.
Phase 3: L-type Ca2+ channels close at ~10mV while IKr potassium rectifier channels open, returning the cell to resting potential
2
Q
What are three factors that determine the rate of spontaneous depolarization of the autorhythmic cells?
A
- Slope of the phase 4 pacemaker potential
- Value of the threshold potential
- Value of the maximum diastolic negative potential
3
Q
Describe Phase 4 of the cardiomyocyte action potential, including the involvement of ion channels/pumps. Explain the significance of potassium in this phase
A
- The resting membrane potential is held at a fairly constant -90mV by the action of the 3Na+/2K+ pump and the 3Na+/Ca2+ exchanger
- Ion concentrations are restored to normal, post-depolarization by the action of these pumps
- The membrane is most permeable to K+, so extracellular potassium has the greatest effect on cardiomyocyte RMP of any ion
4
Q
Describe Phase 0 of the cardiomyocyte action potential, including the involvement of ion channels/pumps.
A
- Influx of positive ions from a neighbouring cardiomyocyte or pacemaker cell causes membrane depolarization.
- If threshold is reached (~70mV) voltage-gated sodium channels and L-type calcium channels open, causing a very rapid inward flux of positive charge
- Membrane rapidly depolarizes to ~+50mV at which point sodium channels close, calcium channels remain open
5
Q
Describe Phase 1 of the cardiomyocyte action potential, including the involvement of ion channels/pumps.
A
- At ~+30mV votlage-gated sodium channels close and Ito1 potassium channels open
- Membrane potential rapidly drops from +30mV
6
Q
Describe Phase 2 of the cardiomyocyte action potential, including the involvement of ion channels/pumps.
A
- “Plateau phase”, corresponds to ST-segment and ventricular systole!
- Efflux of potassium through Ito2, IKR, and IKS potassium rectifier channels is matched by influx of calcium through L-type calcium channels such that there is no net change in membrane potential
- Influx of calcium triggers myofibril contraction
7
Q
Describe Phase 3 of the cardiomyocyte action potential, including the involvement of ion channels/pumps.
A
- “Rapid Repolaization” phase
- L-type calcium channels close while potassium channels remain open
- Additional potassium rectifier channels (Ikr and Iks) and the IK1 channel open as well, allowing increased efflux of potassium
- Membrane rapidly repolarizes to ~-90mV at which point the potassium rectifiers close
8
Q
The absolute/effective refractory period (ERP) spans which phases of the cardiac action potential? What does this correspond to on the ECG?
A
Beginning of phase 0 to middle of phase 3, corresponding to the beginning of the Q-wave to the middle of the T-wave
9
Q
The relative refractory period (RRP) spans which phases of the cardiac action potential? What does this correspond to on the ECG?
A
Spans from the middle of phase 3 to the early part of phase 4, corresponding to the downwards slope of the T-wave.
10
Q
What is the cause of afterdepolarization?
A
abnormal influx of Ca2+ during the RRP, eg: with digitalis toxicity
11
Q
The three main types of arrhythmia are:
A
tachycardias, bradycardias, irregular rhythms
12
Q
The 4 Vaughan-Williams classes of antiarrhythmics are:
A
- Sodium-channel blockers
- Beta-adrenergic blockers
- Potassium-channel blockers
- Calcium-channel blockers
think NaB KC
13
Q
Class 1 antiarrhythmics preferentially bind to sodium channels in the ________ (resting / open / inactivated) state.
A
open and inactivated
14
Q
Xylocaine (Lidocaine)
A
- Class 1B antiarrhythmic
- Preferentially binds to sodium channels in the inactivated state
- Has fast, rate-dependant kinetics. Slows conduction in rapidly depolarizing tissue and limits reentry
- Used in the management of refractory Ventricular arrhythmias, esp. VTach and VFib
- Second-line choice if amiodarone is unsuccessful
15
Q
Class 1 antiarrhythmics delay conduction and extend refractory time, so they are known as ___________
A
membrane stabilizers
16
Q
Class 1 antiarrhythmics only have a significant effect on ________ (atrial / autorhythmic / ventricular) tissue
A
ventricular
17
Q
Iist 4 cardiac effects of the class 2 antiarrhythmics
A
- Decreased automaticity (negative chronotropes)
- Decreased AV nodal conduction (prolonged P-R interval)
- Increased AV node refractory time
- Decreased force of contraction (negative inotropes)
18
Q
Class 2 antiarrhthmics are useful in __________ (life-threatening / non-life-threatening) arrhythmia
A
non-life-threatening
19
Q
Give examples of all three subtypes of class 2 antiarrhythmics
A
Selective β1 - blockers: Atenolol, metoprolol, esmolol
Non-selective β - blockers: Propranolol
α and β blockers: Carvedilol
20
Q
Class 2 antiarrhthmics are useful in __________ (supraventricular / ventricular) arrhythmia
A
supraventricular
21
Q
the class 2 antiarrhythmic best suited to management of acute SVT is _______
A
Parenteral Esmolol
22
Q
The most commonly utilized class 3 antiarrhythmic is __________
A
amiodarone
23
Q
Amiodarone blocks potassium channels, as well as: (list 3)
A
sodium channels, calcium channels, beta-adrenoceptors
24
Q
Class 3 antiarrhythmics exert their effect primarily by:
A
increasing refractory time
25
Amiodarone is generally given orally for __________ and IV for \_\_\_\_\_\_\_\_\_\_
Orally: **supression** of atrial and supraventricular dysrhythmias, VT, and VF
IV: **termination** of VT and VF
26
**Cordarone** (Amiodarone)
* Class 3 antiarrhythmic, potassium channel blocker, thyroxine analog
* also blocks sodium and potassium channels and beta-adrenoceptors
* Decreases SA automaticity, prolongs AV nodal and ventricular refractory periods. Increases PR and QT intervals and may widen QRS.
* Orally given to suppress both supraventricular and ventricular dysrhytmias
* Given IV to terminate VT and VF
* Many adverse effects; bradycardia, torsades de pointes, thyrotoxicity, photosensitivity, pulmonary fibrosis
27
Class 4 antiarrhythmics are primarily used for _________ (supraventricular / ventricular) arrhythmias
supraventricular
28
The calcium channel blockers which function as class 4 antiarrhythmics are:
Diltiazem and verapamil
29
Describe the mechanism of action of diltiazem as an antiarrhythmic
Blocks calcium influx, especially in SA and AV nodes. Prolongs phase 4 and phase 0, leading to a prolonged PR interval and decreased HR
30
Why might calcium channel blockers be particularly useful for patients with angina and AFib?
they act as a class 4 antiarrhythmic and an antianginal (negative inotrope, vasodilator)
31
Diltiazem and verapamil may be used to reduce ventricular rates in patients with _______ (list 2). How do they achieve this?
Atrial Fibrillation and Atrial Flutter. They inhibit AV Nodal conduction
## Footnote
*the autorhythmic cell action potential is largely driven by calcium influx through L-type calcium channels which are inhibited by CCBs*
32
Adenosine (A1) receptors are found in which three locations in the heart?
SA node, Atria, AV Node
33
Adenosine causes _______ (depolarization / hyperpolarization) of AV nodal tissue
hyperpolarization
34
The main indication for adenosine is:
termination of **PSVT**
35
Describe effects of adenosine that are not related to AV nodal blockade
* Decreased HR
* Decreased sensitivity to epinephrine
* Decreased stroke volume
* Increased coronary vasodilation
36
**Adenocard** (Adenosine)
* Antiarrhythmic, endogenous nucleoside, non-Vaughan-Williams class
* Binds to A1 receptors to cause **AV Nodal Blockade** (may cause complete heart block and brief asystole). Causes increased **potassium efflux** and **membrane hyperpolarization**.
* Used to terminate **PSVT**, including in WPW
* Extremely short T1/2 (~10s)
* May cause bronchoconstriction and reduces epinephrine sensitivity
37
Digoxin is indicated as an antiarrhythmic for treatment of \_\_\_\_\_\_\_\_\_\_. Its mechanism of action is \_\_\_\_\_\_\_\_\_\_\_. It ____ (is / is not) the preferred drug for this purpose.
Digoxin is indicated as an antiarrhythmic for treatment of **_atrial fibrillation_**. Its mechanism of action is **_increases vagal tone, decreases AV conduction_**. It **_is not_** the preferred drug for this purpose.
## Footnote
*Digoxin has been shown to increase all-cause mortality in AFib patients and has largely been replaced by CCBs and Beta-blockers in this function*
38
List three cardiac indications for **magnesium sulphate**
1. termination of Torsades de Pointes
2. treat digitalis-induced ventricular dysrhythmias
3. treat supraventricular dysrythmias associated with magnesium deficiency
39
The two goals of rhythm control in active AFib/AFlutter are:
1. control the ventricular rate (Beta-blockers or CCBs)
2. convert to sinus rhythm (ibutilide or DC cardioversion)
40
The most common cause of PSVT is:
a reentrant circuit in the AV Node
41
Describe first-line and second-line pharmacotherapy for acute PSVT (as in WPW)
First line: Rapid IV push of **adenosine**
Second line: AV nodal blockade with **esmolol** or **verapamil**
42
Long-term treatment of PSVT usually involves
surgical ablation of dysrythmogenic tissue
43
The most common cause of **sudden cardiac death** is:
ventricular fibrillation
44
Pharmacologic therapy for VF and VT includes:
* IV infusion of **amiodarone**
* IV Epinephrine in pulseless VF
* IV **Lidocaine** in refractory VF/VT
45
Use the provided chart to summarize treatments for different arrhythmias
46
Define TLC in the management of hyperlipidemia and decribe 4 types
TLC = Therapeutic Lifestyle Changes
1. Diet
2. Exercise
3. Weight Loss
4. Other Changes (smoking cessation, stress reduction)
47
High LDL to HDL ratio is associated with mortality due to \_\_\_\_\_\_\_\_\_\_
atherosclerotic disease
48
Compare and contrast the biological functions of LDL and HDL and their role in atherosclerosis
Both are lipoprotein complexes that allow lipids to be transported in the blood
LDL is used to transport cholesterol from the liver to target tissues, but may also be taken up by macrophages at nascent atheromas to produce foam cells and plaques
HDL is a reverse transporter that is involved in the transport of lipids back to the liver for excretion and is associated with the dissolution of atheromas
49
Describe the mechanism of action of statin medications for hyperlipidemia
statins competitively inhibit HMG-CoA reductase, which catalyzes the rate-determining step in hepatic cholesterol production
50
Adverse effects of statins include:
* muscle pain and potentially life-threatening muscle damage (rhabdo!)
* GI Issues
* Liver damage
* Memory impairment
* NIDDM
51
**Lipitor** (Atorvastatin)
* Statin, antihyperlipidemic
* HMG-CoA inhibitor, reduces LDL by 20-50%
* Shown to reduce mortality due to atherosclerosis
* adverse effects include muscle damage, GI issues, memory impairment, and NIDDM
* Lipitor has a long half life and can be taken at any time of day
52
**Pravachol** (Pravastatin)
* Statin, antihyperlipidemic
* HMG-CoA inhibitor, reduces LDL by 20-50%
* Shown to reduce mortality due to atherosclerosis
* adverse effects include muscle damage, GI issues, memory impairment, and NIDDM
* Pravachol has the lowest rate of adverse effects and drug interactions of any statin
53
Tissue factor (TF) is required to activate the ________ (extrinsic / intrinsic) pathway, the function of which is measured using \_\_\_\_\_\_\_\_
Extrinsic pathway, PT or INR
54
The first clotting factor in the common pathway is factor \_\_\_\_\_, which cleaves ______ into \_\_\_\_\_\_\_\_
The first clotting factor in the common pathway is factor **_X_**, which cleaves **_prothrombin_** into **_thrombin_**
55
Vitamin K is required for the production of clotting factors \_\_\_, \_\_\_, \_\_\_, and \_\_\_. The first clotting factor to be cleared from the blood (due to short T1/2) is factor \_\_\_, which is involved in the ________ (intrinsic / extrinsic) pathway
Vitamin K is required for the production of clotting factors **_II_**, **_VII_**, **_IX_**, and **_X_**. The first clotting factor to be cleared from the blood (due to short T1/2) is factor **_VII_**, which is involved in the **_Extrinsic_** pathway
56
Because warfarin has a delayed onset of action, it is usually co-administered with _______ during initial administration
a low molecular weight heparin
57
**Coumadin** (Warfarin)
* anticoagulant
* Inhibits production of clotting factors II, VII, IX, and X, thereby inhibiting both intrinsic and extrinsic pathways, but especially extrinsic
* Delayed onset of action (3-5 days), initially given with LMWH
* effectiveness is assessed by INR (should be 2-3 for warfarin. 1.1 or less is normal)
* Used in long term **PO** prophylactic treatment for DVT, with artificial heart valves, and AFib
58
The effectiveness of Warfarin is measured using \_\_\_\_
INR
59
While unfractionated and fractionated heparin (LMWH) both promote inactivation of \_\_\_\_\_, only unfractionated heparin promotes inactivation of \_\_\_\_\_\_\_
While unfractionated heparin, fractionated heparin (LMWH), and direct thrombin inhibitors all promote inactivation of **_Factor XA_**, only unfractionated heparin promotes inactivation of **_Thrombin_**
60
Heparin and related drugs act primarily by:
increasing the activity of **antithrombin III (ATIII)**, to inactivate factor Xa, and thrombin (only unfractionated heparin)
61
Unfractionated heparin activity is measured using \_\_\_\_\_
aPTT
62
LMWH drugs _____ (do / do not) require aPTT monitoring
do not!
## Footnote
*low molecular weight heparins have highly predictable anticoagulation*
63
**Heparin** (unfractionated)
* Anticoagulant
* promotes antithrombin III (ATIII) activity, inactivating factor Xa and thrombin.
* Only given parenterally (IV, SC)
* Requires ongoing aPTT monitoring
* Used acutely (PE, DVT, DIC) and prophylactically in surgery or in patients at high risk for clotting disorders
* Antidote is **Protamine** if excessive bleeding is present
64
**Lovenox** (Enoxaparin)
* Anticoagulant, fractionated heparin / LMWH
* promotes antithrombin III (ATIII) activity, inactivating factor Xa
* Only given parenterally (IV, SC)
* **Does not** require ongoing aPTT monitoring
* Used acutely (PE, DVT, DIC) and **mainly prophylactically** in surgery or in patients at high risk for clotting disorders
* Antidote is Protamine if excessive bleeding is present
65
A major hematologic complication of heparin and related drugs is:
Heparin induced thrombocytopenia (HIT)
66
**Protamine** (Protamine sulphate)
* heparin antidote
* used to treat uncontrollable bleeding in the context of heparin administration
67
**Pradaxa** (dabigatran)
* Anticoagulant, direct thrombin inhibitor
* Competitively inhibits thrombin protease site, which inhibits fibrin formation
* no INR monitoring is required
* is increasingly replacing warfarin for chronic management of DVT, AFib due to lower risk of adverse events, no need for monitoring, and fewer food interactions
* **not for patients with valve replacement!**
68
Why is aspirin given in a lower dose for antiplatelet function than for pain management?
ASA is a selective thromboxane A2 inhibitor at low doses, but inhibits prostacyclin at higher doses, which reduces its antiplatelet effect
69
**Aspirin** (Acetylsalicylic acid)
* NSAID, antiplatelet
* non-competitive cyclooxygenase inhibitor. At low doses selectively inhibits thromboxane A2 production without affecting prostacyclins
* prevents platelet aggregation
* given prophylactically or acutely for MI and stroke
70
**Persantine** (Dipyridamole)
* antiplatelet
* relatively weak antiplatelet effect, but also acts as a coronary vasodilator by causing adenosine release
* Often combined with aspirin for post-CVA therapy
71
Describe the general mechanism of action of thrombolytic drugs
they activate plasminogen to plasmin, which degrades fibrin, leading to thrombus dissolution
72
The major indications for fibrinolytic/thrombolytic drugs are:
1. Stroke
2. MI
3. *Pulmonary embolism: relative indication, often first line treatment is with LMWH*
73
The major adverse effect of thrombolytics is:
adverse bleeding
74
**TNKase** (Tenecteplase)
* fibrinolytic, thrombolytic, recombinant tPA
* causes plasmin activation from plasminogen, with high specificity for fibrin-bound plasminogen
* longer duration of action than alteplase
* used in resolution of STEMI
75
**Activase** (Alteplase-Recombinant)
* fibrinolytic, thrombolytic, recombinant tPA
* causes plasmin activation from plasminogen, with moderate-to-high specificity for fibrin-bound plasminogen
* only thrombolytic recommended for acute PE
* also used in stroke and MI management (tenecteplase preferred for STEMI)
76
**TXA** (Tranexamic Acid)
* procoagulant, antiplasmin
* inhibits activation of plasmin from plasminogen
* used in management of heavy menstrual bleeding, hemophilia, and **traumatic hemorrhage**
77
Iron deficiency causes a ________ (hyperchromic / hypochromic) _________ (macrocytic / mycrocytic) anemia
hypochromic, microcytic anemia
78
iron is transported in blood bound to ________ and is stored in cells bound to \_\_\_\_\_\_\_\_
trasnferrin, ferritin
79
The major adverse effects of iron supplementation are:
* GI distress
* N/V
* Black stools
80
Deficiency in folic acid may lead to: (list 2)
* congenital abnormalities (spinda bifida)
* Megaloblastic anemia
81
vitamin B12 causes a _________ anemia
megaloblastic
82
Care most be taken when giving folate supplementation because it can mask a _________ deficiency
vitamin B12
83
The most powerful class of V-W antiarrhythmic in extending ERP is:
Class III - Potassium-channel blockers
84
What are the three categories of antithrombotics? Give an example of each.
1. Anticoagulants (inhibit fibrin formation)
* Warfarin, Heparin, Deltaparin, Tinzaparin, **Dabigitran**
2. Antiplatelets (inhibit platelet aggregation)
* Aspirin, clopidogrel, persantine
3. Thrombolytics/fibrinolytics (promote clot breakdown by plasmin)
* Tenecteplase, Alteplase
